Cadrenal Therapeutics, Inc. 8K

Cadrenal Therapeutics launched a formal partnering and out-licensing process for its reorganized Cardiac Acute Critical Care Franchise following positive Phase 2 data for CAD-1005 and outlined the strategic development status of its late-stage and preclinical cardiovascular assets.

On July 21, 2026, Cadrenal Therapeutics, Inc. announced that it has reorganized its pipeline into a Cardiac Acute Critical Care Franchise and initiated a structured partnering process aimed at securing strategic out-licensing, portfolio monetization, or co-development agreements for its late-stage cardiovascular assets CAD-1005, frunexian, and tecarfarin, following the presentation of favorable Phase 2 data for CAD-1005 at the ISTH 2026 Congress that showed more than a 25% absolute reduction in thrombotic events in heparin-induced thrombocytopenia patients; the company also highlighted Phase 3 readiness for CAD-1005 and parts of its portfolio, potential orphan and priority review voucher opportunities for tecarfarin, and ongoing development of its preclinical oral 12-LOX inhibitor CAD-2000 to extend its platform into chronic cardiorenal indications.

Filing Facts

CIK

1937993

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-079824

Alert Tier

6